Peter Hillmen

Summary

Country: UK

Publications

  1. ncbi request reprint Minimal residual disease and survival in chronic lymphocytic leukemia
    Peter Hillmen
    Clin Adv Hematol Oncol 3:522-4. 2005
  2. pmc Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria
    Peter Hillmen
    St James s University Hospital, Leeds, UK
    Br J Haematol 162:62-73. 2013
  3. doi request reprint Using the biology of chronic lymphocytic leukemia to choose treatment
    Peter Hillmen
    Institute of Oncology, St James s University Hospital, Leeds, United Kingdom
    Hematology Am Soc Hematol Educ Program 2011:104-9. 2011
  4. ncbi request reprint Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia
    Peter Hillmen
    Leeds Teaching Hospitals National Health Service Trust, Leeds General Infirmary, Leeds, United Kingdom
    J Clin Oncol 25:5616-23. 2007
  5. ncbi request reprint Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria
    Peter Hillmen
    Leeds General Infirmary, Leeds, United Kingdom
    Blood 110:4123-8. 2007
  6. ncbi request reprint Beyond detectable minimal residual disease in chronic lymphocytic leukemia
    Peter Hillmen
    Leeds General Infirmary, Leeds, UK
    Semin Oncol 33:S23-8. 2006
  7. ncbi request reprint The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria
    Peter Hillmen
    Leeds General Infirmary, Leeds, United Kingdom
    N Engl J Med 355:1233-43. 2006
  8. doi request reprint A randomized phase II trial of fludarabine, cyclophosphamide and mitoxantrone (FCM) with or without rituximab in previously treated chronic lymphocytic leukaemia
    Peter Hillmen
    Department of Haematology, Leeds Teaching Hospitals NHS Trust, St James s University Hospital, Beckett Street, Leeds, UK
    Br J Haematol 152:570-8. 2011
  9. doi request reprint Long-term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria
    Peter Hillmen
    Department of Hematology, St James s Institute of Oncology, Leeds, United Kingdom
    Am J Hematol 85:553-9. 2010
  10. pmc Eculizumab prevents intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria and unmasks low-level extravascular hemolysis occurring through C3 opsonization
    Anita Hill
    1Department of Haematology, St James University Hospital, Leeds, UK
    Haematologica 95:567-73. 2010

Detail Information

Publications62

  1. ncbi request reprint Minimal residual disease and survival in chronic lymphocytic leukemia
    Peter Hillmen
    Clin Adv Hematol Oncol 3:522-4. 2005
  2. pmc Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria
    Peter Hillmen
    St James s University Hospital, Leeds, UK
    Br J Haematol 162:62-73. 2013
    ..Eculizumab has a substantial impact on the symptoms and complications of PNH and results a significant improvement in patient survival...
  3. doi request reprint Using the biology of chronic lymphocytic leukemia to choose treatment
    Peter Hillmen
    Institute of Oncology, St James s University Hospital, Leeds, United Kingdom
    Hematology Am Soc Hematol Educ Program 2011:104-9. 2011
    ....
  4. ncbi request reprint Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia
    Peter Hillmen
    Leeds Teaching Hospitals National Health Service Trust, Leeds General Infirmary, Leeds, United Kingdom
    J Clin Oncol 25:5616-23. 2007
    ..We conducted a randomized trial to evaluate the efficacy and safety of intravenous alemtuzumab compared with chlorambucil in first-line treatment of chronic lymphocytic leukemia (CLL)...
  5. ncbi request reprint Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria
    Peter Hillmen
    Leeds General Infirmary, Leeds, United Kingdom
    Blood 110:4123-8. 2007
    ..001). These results show that eculizumab treatment reduces the risk of clinical thromboembolism in patients with PNH. This study is registered at http://clinicaltrials.gov (study ID no. NCT00122317)...
  6. ncbi request reprint Beyond detectable minimal residual disease in chronic lymphocytic leukemia
    Peter Hillmen
    Leeds General Infirmary, Leeds, UK
    Semin Oncol 33:S23-8. 2006
    ..This article reviews recent advances in identifying patients who have poor-risk disease and explores the potential importance of MRD status as an outcome measure of CLL therapy...
  7. ncbi request reprint The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria
    Peter Hillmen
    Leeds General Infirmary, Leeds, United Kingdom
    N Engl J Med 355:1233-43. 2006
    ..We tested the safety and efficacy of eculizumab, a humanized monoclonal antibody against terminal complement protein C5 that inhibits terminal complement activation, in patients with paroxysmal nocturnal hemoglobinuria (PNH)...
  8. doi request reprint A randomized phase II trial of fludarabine, cyclophosphamide and mitoxantrone (FCM) with or without rituximab in previously treated chronic lymphocytic leukaemia
    Peter Hillmen
    Department of Haematology, Leeds Teaching Hospitals NHS Trust, St James s University Hospital, Beckett Street, Leeds, UK
    Br J Haematol 152:570-8. 2011
    ..Efficacy and safety should be fully tested in a randomized Phase III trial...
  9. doi request reprint Long-term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria
    Peter Hillmen
    Department of Hematology, St James s Institute of Oncology, Leeds, United Kingdom
    Am J Hematol 85:553-9. 2010
    ..Administration of eculizumab to patients with renal dysfunction or damage was well tolerated and was usually associated with clinical improvement...
  10. pmc Eculizumab prevents intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria and unmasks low-level extravascular hemolysis occurring through C3 opsonization
    Anita Hill
    1Department of Haematology, St James University Hospital, Leeds, UK
    Haematologica 95:567-73. 2010
    ..This may be due to C3-mediated clearance of paroxysmal nocturnal hemoglobinuria red blood cells through the reticuloendothelial system...
  11. ncbi request reprint Sustained response and long-term safety of eculizumab in paroxysmal nocturnal hemoglobinuria
    Anita Hill
    Department of Haematology, Leeds Teaching Hospitals NHS Trust, Leeds, LS1 3EX, United Kingdom
    Blood 106:2559-65. 2005
    ..Eculizumab continued to be safe and well tolerated, and all patients completed the study. The close relationship between sustained terminal complement inhibition, hemolysis, and symptoms was demonstrated...
  12. doi request reprint Eradicating minimal residual disease in chronic lymphocytic leukemia: should this be the goal of treatment?
    Abraham M Varghese
    Department of Haematology, St James s Institute of Oncology, Leeds, UK
    Curr Hematol Malig Rep 5:35-44. 2010
    ..This article reviews our current understanding of MRD eradication and analyzes whether it is a desirable goal in the routine clinical treatment of CLL, which will optimize the management of individual patients...
  13. doi request reprint Chronic lymphocytic leukaemia (CLL) and CLL-type monoclonal B-cell lymphocytosis (MBL) show differential expression of molecules involved in lymphoid tissue homing
    Andy C Rawstron
    HMDS, St James s Institute of Oncology, Leeds, United Kingdom
    Cytometry B Clin Cytom 78:S42-6. 2010
    ..The aim of this study was to screen for cell surface markers that could discriminate CLL-type MBL from CLL or identify CLL cases likely to have stable disease...
  14. doi request reprint Effect of eculizumab on haemolysis-associated nitric oxide depletion, dyspnoea, and measures of pulmonary hypertension in patients with paroxysmal nocturnal haemoglobinuria
    Anita Hill
    Department of Haematology, St James s Institute of Oncology, Leeds
    Br J Haematol 149:414-25. 2010
    ..These data demonstrated that intravascular haemolysis in PNH produces a state of NO catabolism leading to signs of PH, including elevated NT pro-BNP and dyspnoea that are significantly improved by treatment with eculizumab...
  15. doi request reprint Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia
    Andy C Rawstron
    Haematological Malignancy Diagnostic Service, Leeds Teaching Hospitals, Leeds, United Kingdom
    N Engl J Med 359:575-83. 2008
    ..Asymptomatic persons with fewer CLL-phenotype cells have monoclonal B-cell lymphocytosis (MBL). The goal of this study was to investigate the relation between MBL and CLL...
  16. ncbi request reprint Improvement in the symptoms of smooth muscle dystonia during eculizumab therapy in paroxysmal nocturnal hemoglobinuria
    Anita Hill
    Haematology, Leeds Teaching Hospitals NHS Trust, UK
    Haematologica 90:ECR40. 2005
    ..Complement inhibition has been sustained for over 2 years and results in resolution of intravascular hemolysis and amelioration of symptoms associated with smooth muscle contractions...
  17. ncbi request reprint Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria
    Peter Hillmen
    Department of Haematology, Leeds Teaching Hospitals National Health Science Trust, Leeds, United Kingdom
    N Engl J Med 350:552-9. 2004
    ..We tested the clinical efficacy of eculizumab, a humanized antibody that inhibits the activation of terminal complement components, in patients with PNH...
  18. ncbi request reprint Recent developments in the understanding and management of paroxysmal nocturnal haemoglobinuria
    Anita Hill
    Department of Haematology, Leeds Teaching Hospitals NHS Trust, Great George Street, Leeds, UK
    Br J Haematol 137:181-92. 2007
    ....
  19. ncbi request reprint Minimal residual disease assessment in chronic lymphocytic leukaemia
    Hazem A Sayala
    Haematological Malignancy Diagnostic Service, Leeds General Infirmary, Great George Street, Leeds LS1 3EX, UK
    Best Pract Res Clin Haematol 20:499-512. 2007
    ..In this chapter we briefly review the existing methods for MRD assessment, the clinical relevance of MRD eradication in CLL, and the therapies available to attain this endpoint...
  20. ncbi request reprint Recent advances in the diagnosis, monitoring, and management of patients with paroxysmal nocturnal hemoglobinuria
    Stephen J Richards
    Haematological Malignancy Diagnostic Service, Department of Haematology, Leeds Teaching Hospitals NHS Trust, The Algernon Firth Building, Leeds General Infirmary, Leeds, LS1 3EX, United Kingdom
    Cytometry B Clin Cytom 72:291-8. 2007
    ..In both these developments, flow cytometry played a critical role. In the first instance, in monitoring direct response to a new therapeutic agent; second, in demonstrating the phenotypic/genotypic link in a new form of GPI deficiency...
  21. ncbi request reprint Early prediction of outcome and response to alemtuzumab therapy in chronic lymphocytic leukemia
    Andy C Rawstron
    Academic Unit of Haematology and Oncology, Haematological Malignancy Diagnostic Service, Leeds General Infirmary, United Kingdom
    Blood 103:2027-31. 2004
    ..If validated in prospective studies, blood monitoring at 2 and 4 weeks may be used to optimize therapy...
  22. doi request reprint The management of pregnancy in paroxysmal nocturnal haemoglobinuria on long term eculizumab
    Richard Kelly
    Institute of Oncology, St James s University Hospital, Leeds, UK
    Br J Haematol 149:446-50. 2010
    ..There was no evidence of complement blockade from cord blood samples taken at delivery. Eculizumab appears safe to use in this setting and is likely to prevent many of the complications usually observed...
  23. ncbi request reprint Protection of erythrocytes from human complement-mediated lysis by membrane-targeted recombinant soluble CD59: a new approach to PNH therapy
    Anita Hill
    Haematological Malignancy Diagnostic Service, Leeds Teaching Hospitals National Health Service Trust, Algernon Firth Building, Great George Street, Leeds, United Kingdom, LS1 3EX
    Blood 107:2131-7. 2006
    ..Thus, rhCD59-P corrects the CD59 deficiency in vitro and can bind to erythrocytes in an in vivo murine model, protecting the cells from the activity of human complement, and represents a potential therapeutic strategy in PNH...
  24. ncbi request reprint The biological and clinical relationship between CD5+23+ monoclonal B-cell lymphocytosis and chronic lymphocytic leukaemia
    Andy C Rawstron
    HMDS, Leeds Teaching Hospitals, Leeds, UK
    Br J Haematol 139:724-9. 2007
    ....
  25. doi request reprint Immunophenotypic analysis of PNH cells
    Stephen J Richards
    Haematological Malignancy Diagnostic Service, Leeds, United Kingdom
    Curr Protoc Cytom . 2002
    ....
  26. doi request reprint Different biology and clinical outcome according to the absolute numbers of clonal B-cells in monoclonal B-cell lymphocytosis (MBL)
    Andy C Rawstron
    HMDS, Department of Hematology, St James s Institute of Oncology, Leeds, United Kingdom
    Cytometry B Clin Cytom 78:S19-23. 2010
    ....
  27. ncbi request reprint Superior quality and duration of responses among patients with mantle-cell lymphoma treated with fludarabine and cyclophosphamide with or without rituximab compared with prior responses to CHOP
    D Wayne Thomas
    Department of Haematology, Derriford Hospital, Plymouth, UK
    Leuk Lymphoma 46:549-52. 2005
    ..07 vs. CHOP), and a median duration of response of 11 months (4-25+ months). This study demonstrates that FC is a highly active regimen in patients relapsing following CHOP chemotherapy...
  28. doi request reprint Development and evaluation of a stabilized whole-blood preparation as a process control material for screening of paroxysmal nocturnal hemoglobinuria by flow cytometry
    Stephen J Richards
    Haematological Malignancy Diagnostic Service, St James s University Hospital, Leeds LS9 7TF, United Kingdom
    Cytometry B Clin Cytom 76:47-55. 2009
    ..Currently, no external quality assessment (EQA) programme or reference material is available for whole-blood PNH testing (red cells and leucocytes) by flow cytometry...
  29. doi request reprint Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival
    Richard J Kelly
    Department of Haematology, Leeds Teaching Hospitals, Leeds, UK
    Blood 117:6786-92. 2011
    ..001). Eculizumab dramatically alters the natural course of PNH, reducing symptoms and disease complications as well as improving survival to a similar level to that of the general population...
  30. doi request reprint Under-recognized complications in patients with paroxysmal nocturnal haemoglobinuria: raised pulmonary pressure and reduced right ventricular function
    Anita Hill
    Department of Haematology, St James s Institute of Oncology, Leeds, UK
    Br J Haematol 158:409-14. 2012
    ..Together, these data suggest a high prevalence of haemolysis-associated NO scavenging, Doppler-estimated systolic pulmonary hypertension, and depressed right ventricular function in patients with PNH...
  31. ncbi request reprint Hypomorphic promoter mutation in PIGM causes inherited glycosylphosphatidylinositol deficiency
    Antonio M Almeida
    Department of Haematology, Imperial College London, Hammersmith Hospital, Du Cane Road, London, W12, 0NN, UK
    Nat Med 12:846-51. 2006
    ..These findings indicate that biosynthesis of GPI is essential to maintain homeostasis of blood coagulation and neurological function...
  32. ncbi request reprint Primary prophylaxis with warfarin prevents thrombosis in paroxysmal nocturnal hemoglobinuria (PNH)
    Claire Hall
    The Haematological Malignancy Diagnostic Service, Algernon Firth Building, Leeds General Infirmary, Great George Street, Leeds, LS1 3EX, United Kingdom
    Blood 102:3587-91. 2003
    ..Large PNH granulocyte clones are predictive of venous thrombosis, although the exact cut-off for clone size is still to be determined. Primary prophylaxis with warfarin in PNH prevents thrombosis with acceptable risks...
  33. doi request reprint Thrombosis in paroxysmal nocturnal hemoglobinuria
    Anita Hill
    Department of Haematology, St James s University Hospital, Leeds, United Kingdom
    Blood 121:4985-96; quiz 5105. 2013
    ..Complement inhibition with eculizumab has a dramatic effect in PNH and has a major impact in the prevention of thrombosis as well as its management in this disease...
  34. pmc The pathophysiology of paroxysmal nocturnal hemoglobinuria and treatment with eculizumab
    Richard Kelly
    Institute of Oncology, St James s University Hospital, Leeds, UK
    Ther Clin Risk Manag 5:911-21. 2009
    ..It is not a curative therapy but has a great benefit on those with this rare debilitating condition...
  35. ncbi request reprint Outreach monitoring service for patients with indolent B-cell and plasma cell disorders: a UK experience
    Andy C Rawstron
    HMDS Department, Leeds Teaching Hospitals, Leeds, UK
    Br J Haematol 139:845-8. 2007
    ....
  36. ncbi request reprint MRD in CLL
    Peter Hillmen
    Leeds Teaching Hospitals NHS Trust, UK
    Clin Adv Hematol Oncol 4:6-7; discussion 10; suppl 12. 2006
  37. ncbi request reprint Future prospects for fludarabine-containing regimens in the treatment of hematological cancers
    Peter Hillmen
    Haematology Malignancy Diagnostic Service HMDS, Algernon Firth Building, Leeds General Infirmary, Leeds, UK
    Hematol J 5:S76-86. 2004
    ..The successful application of fludarabine plus alemtuzumab, or fludarabine in combination with other cytotoxic agents, as preparative regimens for stem cell transplantation techniques is also covered...
  38. doi request reprint Clinical and diagnostic implications of monoclonal B-cell lymphocytosis
    Andy C Rawstron
    Haematological Malignancy Diagnostic Service, St James s Institute of Oncology, Bexley Wing, Beckett Street, Leeds LS9 7TF, UK
    Best Pract Res Clin Haematol 23:61-9. 2010
    ..In addition, we will evaluate the importance of further clinical investigations, in particular, the relevance of screening for MBL and undertaking bone marrow investigations according to the clinical setting and B-cell phenotype...
  39. ncbi request reprint B-cell chronic lymphocytic leukaemia cells show specific changes in membrane protein expression during different stages of cell cycle
    Fiona Bennett
    Haematological Malignancy Diagnostic Service, Leeds Teaching Hospitals, Leeds, UK
    Br J Haematol 139:600-4. 2007
    ..The results suggest continuous re-entry into the cell cycle as no distinct stem cell pool was detectable...
  40. ncbi request reprint Immunological effects and safe administration of alemtuzumab (MabCampath) in advanced B-cLL
    Ben Kennedy
    Leeds General Infirmary, UK
    Med Oncol 19:S49-55. 2002
    ..With protocols in place for dose escalation, for dose postponement in the event of cytopenia, and for anti-infective prophylaxis, alemtuzumab can be used effectively and safely in high-risk B-CLL patients...
  41. ncbi request reprint The glycosylphosphatidylinositol anchor and paroxysmal nocturnal haemoglobinuria/aplasia model
    Claire Hall
    Haematological Malignancy Diagnostic Service, Leeds General Infirmary, Leeds, UK
    Acta Haematol 108:219-30. 2002
    ..Gene therapy remains a tantalising possibility, although a greater understanding of the pathophysiology of PNH is required, as well as advances in gene therapy techniques, before such an approach can be seriously considered...
  42. doi request reprint Assessing minimal residual disease in chronic lymphocytic leukemia
    Andy C Rawstron
    Haematological Malignancy Diagnostic Service, Leeds Teaching Hospitals, Leeds, UK
    Curr Hematol Malig Rep 3:47-53. 2008
    ..MRD analysis in the peripheral blood also may be used during therapy to predict eventual response and potentially to guide therapy to achieve the optimal outcome...
  43. ncbi request reprint Management guidelines for use of alemtuzumab in B-cell chronic lymphocytic leukemia
    Michael Keating
    M D Anderson Cancer Center, Houston, TX 77030, USA
    Clin Lymphoma 4:220-7. 2004
    ..Because high response rates and few complications are observed in previously untreated patients, the use of alemtuzumab earlier in therapy may provide optimum benefit to patients...
  44. ncbi request reprint Advancing therapy for chronic lymphocytic leukemia--the role of rituximab
    Peter Hillmen
    Pinderfields General Hospital, Aberford Road, Wakefield WF1 4DG, UK
    Semin Oncol 31:22-6. 2004
    ..The combination of rituximab with other agents is also being investigated, and these ongoing trials will help define the role of rituximab in CLL...
  45. ncbi request reprint CD52 expression in Waldenstrom's macroglobulinemia: implications for alemtuzumab therapy and response assessment
    Roger G Owen
    Haematological Malignancy Diagnostic Service Laboratory, The Leeds Teaching Hospitals NHS Trust, General Infirmary at Leeds, Great George Street, Leeds LS1 3EX, UK
    Clin Lymphoma 5:278-81. 2005
    ..The implications of these findings for monoclonal antibody therapy in WM are discussed...
  46. ncbi request reprint The prognostic significance of a positive direct antiglobulin test in chronic lymphocytic leukemia: a beneficial effect of the combination of fludarabine and cyclophosphamide on the incidence of hemolytic anemia
    Claire Dearden
    Royal Marsden National Health Service NHS Foundation Trust and Institute of Cancer Research, Sutton, Surrey, UK
    Blood 111:1820-6. 2008
    ..In conclusion, DAT status at the time of initiation of therapy provides a new prognostic indicator, although FC may protect against AHA. This trial was registered at http://isrctn.org as no. 58585610...
  47. ncbi request reprint Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria
    Robert A Brodsky
    Johns Hopkins School of Medicine, Baltimore, MD 21205, USA
    Blood 111:1840-7. 2008
    ..This trial is registered at http://clinicaltrials.gov as NCT00130000...
  48. ncbi request reprint Alemtuzumab therapy in B-cell lymphoproliferative disorders
    Paul Moreton
    Haematological Malignancy Diagnostic Service, University of Leeds, UK
    Semin Oncol 30:493-501. 2003
    ..Infectious complications are the most important toxicity seen and are related to the depletion of normal lymphocytes. The clinical efficacy in combination with both fludarabine and rituximab is under investigation...
  49. ncbi request reprint Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival
    Paul Moreton
    Leeds Teaching Hospitals, NHS Trust, Great George St, Leeds, LS1 3EX United Kingdom
    J Clin Oncol 23:2971-9. 2005
    ..To test whether eradication of minimal residual disease (MRD) in B-cell chronic lymphocytic leukemia (CLL) by alemtuzumab is associated with a prolongation of treatment-free and overall survival...
  50. ncbi request reprint The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease
    Russell P Rother
    Alexion Pharmaceuticals, Cheshire, Conn 06410, USA
    JAMA 293:1653-62. 2005
    ..A growing list of clinical manifestations attributed to hemoglobin release in a variety of acquired and iatrogenic hemolytic disorders suggests that hemolysis and hemoglobinemia should be considered as a novel mechanism of human disease...
  51. ncbi request reprint Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study
    Michael J Keating
    M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 99:3554-61. 2002
    ..Alemtuzumab induced significant responses in these patients with clinical benefit in the majority and with acceptable toxicity in a high-risk group...
  52. ncbi request reprint Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia
    Ben Kennedy
    Haematological Malignancy Diagnostic Service, Institute of Pathology, Algernon Firth Building, University of Leeds, Leeds LS2 9JT, West Yorkshire, UK
    Blood 99:2245-7. 2002
    ..Complete morphologic bone marrow responses were seen in 3 patients, including eradication of disease measured by sensitive flow cytometry in 2. Campath-1H combined with fludarabine is a highly promising novel therapy for refractory CLL...
  53. ncbi request reprint Monoclonal B lymphocytes with the characteristics of "indolent" chronic lymphocytic leukemia are present in 3.5% of adults with normal blood counts
    Andy C Rawstron
    Haematological Malignancy Diagnostic Service, Academic Unit of Haematology and Oncology, Algernon Firth Building, University of Leeds, United Kingdom
    Blood 100:635-9. 2002
    ..8%-6.6%) of IgH somatic hypermutation. The monoclonal CLL phenotype cells present in otherwise healthy individuals may represent a very early stage of indolent CLL and should be useful in elucidating the mechanisms of leukemogenesis...
  54. ncbi request reprint Inherited predisposition to CLL is detectable as subclinical monoclonal B-lymphocyte expansion
    Andy C Rawstron
    Academic Unit of Haematology and Oncology, University of Leeds, HMDS, West Yorkshire, Surrey, United Kingdom
    Blood 100:2289-90. 2002
    ..The detection of CLL-phenotype cells provides a surrogate marker of carrier status, potentially facilitating gene identification through mapping in families and direct analysis of isolated CLL-phenotype cells...
  55. doi request reprint A genome-wide association study identifies six susceptibility loci for chronic lymphocytic leukemia
    Maria Chiara Di Bernardo
    Section of Cancer Genetics, Institute of Cancer Research, Sutton, Surrey, UK
    Nat Genet 40:1204-10. 2008
    ..32 (rs11083846, PRKD2; P = 3.96 x 10(-9)). These data provide the first evidence for the existence of common, low-penetrance susceptibility to a hematological malignancy and new insights into disease causation in CLL...
  56. ncbi request reprint Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration
    Geoff Hale
    Therapeutic Antibody Centre, Old Road, Headington, Oxford, OX3 7JT, United Kingdom
    Blood 104:948-55. 2004
    ..Subcutaneous alemtuzumab is more convenient and better tolerated but may be associated with some patients forming anti-alemtuzumab antibodies, particularly those patients who were previously untreated...
  57. ncbi request reprint Clonal lymphocytes in persons without known chronic lymphocytic leukemia (CLL): implications of recent findings in family members of CLL patients
    Andy Rawstron
    HMDS, Leeds Teaching Hospitals, UK
    Semin Hematol 41:192-200. 2004
    ..The data suggest that inherited factors increase the susceptibility to both indolent and aggressive CLL, and they provide unbiased demonstration that the age of onset in CLL families is younger than in the general population...
  58. ncbi request reprint Minimal residual disease in chronic lymphocytic leukaemia: is it ready for primetime?
    Chadi Nabhan
    Division of Hematology and Oncology, Lutheran General Hospital Cancer Center, Park Ridge, IL, USA
    Br J Haematol 136:379-92. 2007
    ....
  59. ncbi request reprint Diagnostic criteria for monoclonal B-cell lymphocytosis
    Gerald E Marti
    Center for Biologics Evaluation and Research CBER, US Food and Drug Administration FDA, NIH, Bethesda, MD, USA
    Br J Haematol 130:325-32. 2005
    ..Future studies of MBL should be directed towards determining its relationship to clinical disease, particularly in individuals from families with a genetic predisposition to developing CLL...
  60. ncbi request reprint CD52 expression patterns in myeloma and the applicability of alemtuzumab therapy
    Andy C Rawstron
    Haematologica 91:1577-8. 2006
    ..The data suggest that myeloma plasma cells are unlikely to be depleted by alemtuzumab in most patients...
  61. pmc Diagnosis and management of paroxysmal nocturnal hemoglobinuria
    Charles Parker
    Division of Hematology, University of Utah School of Medicine and Hematology Oncology Section 111H, George E Whalen VA Medical Center, Salt Lake City, UT 84148, USA
    Blood 106:3699-709. 2005
  62. ncbi request reprint Perspectives on the use of new diagnostic tools in the treatment of chronic lymphocytic leukemia
    Jacques Louis Binet
    Rebecca and John Moores Cancer Center, University of California, San Diego, La Jolla, CA 92093 0663, USA
    Blood 107:859-61. 2006
    ..Pending the outcome of such trials, treatment decisions outside the context of a clinical trial still should be based on guidelines established by the most recent National Cancer Institute-sponsored Working Group...